HUNTINGTONS DISEASE TREATMENT MARKET ANALYSIS

Huntington’s Disease Treatment Market, By Drug Type (Tetrabenazine, Deutetrabenazine, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook and Opportunity Analysis, 2022-2028

Published In : Sep 2023
Code : CMI1479
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Huntington’s disease Treatment Market Driver:

Currently, Huntington’s disease has no cure, therefore, the treatment available in the market aid in slowing down degeneration of the neurons. Huntington’s disease treatment market is dominated by off-labeled drugs, which creates opportunity for key players, to develop new drugs. Austedo, a generic of deutetrabenazine by Teva Pharmaceutical Industries Ltd., received FDA approval in 2017 and became second FDA approved drug for Huntington’s disease after Xenazine. Furthermore, Laquinimod and Pridopidine are in Phase 2 clinical trials for the treatment of Huntington’s disease. Moreover, tetrabenazine is been studied by Lundbeck, in 2017, for its ability to reduce impulsiveness, depression, and suicidal tendencies for patients suffering from Huntington’s disease and it is in Phase 4 clinical trials. This increase in R&D activities and strong company pipelines are factors expected to fuel growth of the global Huntington’s disease treatment market.